Orchidia certified with WHO-GMP implementation from the Egyptian Drug Authority EDA and other countries of registration in the Middle East and Africa, ISO 9001:2015, ISO 14001:2015, ISO 45001:2018, ISO 17025:2017, ISO 13485:2016, and European CE mark. We maintain and continually improve our Quality Management Systems (QMS) and Environmental Health and Safety (EHS) to achieve the required quality level and exceed the expectations of our stakeholders. Our current portfolio includes 60 ophthalmic drugs, and 11 medical devices with 8 obtain the CE marked certificates. In addition to a rich pipeline in different ophthalmic Products in different ophthalmic Dosage forms. Our CE products are registered in Belgium MOH by SGS Belgium 1639 and by the German-authorized representative MDSS ( Medical Device Safety Services). Orchidia products are available outside our national borders in 40 countries, mainly in MEA region. The company is in the process of registration in several countries.

Orchidia operates advanced sterile production lines, including two Rommelag BFS multi-dose machines (5, 10, 15 ml) using fully automated Blow-Fill-Seal technology without human intervention, and an SDU BFS machine (0.2–0.6 ml). In 2017, the company entered the preservative-free market by acquiring its first SDU, increasing its domestic and global share. As demand grew in 2021, Orchidia invested in a new high-capacity SDU to be installed by end of 2023, ensuring sufficient production for the next five years. The facility also includes three conventional sterile filling lines, a CAM line for contact lens solutions, and two sterile filling machines (IMA & B+S). All operations occur in highly classified cleanrooms under strict monitoring and validation. Orchidia also runs an IWK semi-solid filling line (5 & 10 g) and two automated packaging lines with Track & Trace, producing eye drops, contact lens solutions, gels, suspensions, preservative-free SDUs, and sterile semi-solids.